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A B S T R A C T
Purpose
To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced
hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial.
Patients and Methods
Patients with advanced HCC and underlying Child-Pugh class A cirrhosis, who were naive to
systemic treatment (N  720), were randomly assigned to sorafenib plus either erlotinib (n  362)
or placebo (n  358). The primary end point was overall survival (OS).
Results
Median OS was similar in the sorafenib plus erlotinib and sorafenib plus placebo groups (9.5 v 8.5 months,
respectively; hazard ratio [HR], 0.929; P  .408), as was median time to progression (3.2 v 4.0 months,
respectively; HR, 1.135;P .18). In the sorafenib/erlotinib arm versus the sorafenib/placebo arm, the overall
response rate trended higher (6.6% v 3.9%, respectively; P .102), whereas the disease control rate was
significantly lower (43.9% v 52.5%, respectively; P  .021). The median durations of treatment with
sorafenib were 86 days in the sorafenib/erlotinib arm and 123 days in the sorafenib/placebo arm. In the
sorafenib/erlotinib and sorafenib/placebo arms, the rates of treatment-emergent serious AEs (58.0% v
54.6%, respectively) and drug-related serious AEs (21.0% v 22.8%, respectively) were similar. AEs
matched the known safety profiles of both agents, but rates of rash/desquamation, anorexia, and diarrhea
were higher in the sorafenib/erlotinib arm, whereas rates of alopecia and hand-foot skin reaction were
higher in the sorafenib/placebo arm. Withdrawal rates for AEs during cycles 1 to 3 were higher in the
sorafenib/erlotinib arm.
Conclusion
Adding erlotinib to sorafenib did not improve survival in patients with advanced HCC.
J Clin Oncol 33:559-566. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third most
frequent cause of cancer deaths worldwide.1 Most
patients are diagnosed at advanced stages, when cu-
rative treatments, including resection, liver trans-
plantation, and ablation, are no longer available.2,3
At present, sorafenib, a multikinase inhibitor, is the
only systemic agent approved to treat advanced, un-
resectable HCC,3-5 based on two phase III trials
showing that sorafenib significantly improved sur-
vival in these patients.6,7
Other targeted agents, alone or combined with
sorafenib, have been tested in patients with HCC.8,9
The epidermal growth factor receptor (EGFR)path-
way has been implicated in the pathogenesis of
HCC.10,11 EGFR activationmay interfere withHCC
response to sorafenib,11-13 suggesting that EGFR in-
hibition may enhance tumor response. Erlotinib is
an orally active inhibitor of EGFR tyrosine kinase14,15
approved to treat patients with advanced non–
small-cell lung and pancreatic cancers.16 More-
over, in two single-arm, phase II trials, erlotinib
showed modest antitumor activity but promis-
ing overall survival (OS) benefit in patients with
unresectable HCC.17,18
Because sorafenib and erlotinib target different
pathways, treatment with bothmay have synergistic
or additive inhibitory effects on tumor growth. In a
phase I trial, the combination showed promising
antitumor activity in patients with solid tumors, in-
cludingHCC.19 To determine whether the addition
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of erlotinib improves the efficacy of sorafenib in patients with ad-
vanced HCC, a phase III trial compared the efficacy and safety of
first-line sorafenib/erlotinib with sorafenib/placebo in these patients.
PATIENTS AND METHODS
Patient Selection
The SEARCH (Sorafenib and Erlotinib, a Randomized Trial Pro-
tocol for the Treatment of Patients With Hepatocellular Carcinoma)
study was a randomized, double-blind, placebo-controlled, phase III
trial conducted at 128 centers in 26 countries in Europe, North and South
America, and theAsia-Pacific region, enrolling patients age 18 yearswith
histologically or radiologically confirmed advanced/metastatic HCC not
amenable to local therapies. All patients had one or more measurable
lesions according to RECIST, Child-Pugh class A (determined during
screening), life expectancy 12 weeks, and Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1. Patients who previously
received local therapy (eg, surgery, transcatheter arterial chemoemboliza-
tion, or radiofrequency ablation) were eligible if therapy was completed
4weeks before baseline scan and the previously treated lesions could not be
selected as target lesions. All patients had adequate hematologic, hepatic,
and kidney function, including a platelet count 60 109/L, hemoglobin
 8.5 g/dL, total bilirubin  2.8 mg/dL, ALT and AST  5 the upper
limit of normal, serum creatinine 1.5 the upper limit of normal, and
prothrombin time–international normalized ratio  2.3 or prothrombin
time 6 seconds above control.
Exclusion criteria included the following: prior systemic treatment for
HCC; concurrent cancer (except for squamous cell carcinoma in situ, cervical
cancer, superficial bladder cancer or cancer cured 3 years before trial entry);
renal failure requiringhemodialysis orperitonealdialysis; historyof cardiovas-
cularorperipheral vasculardisease; active, serious clinical infection (except for
hepatitis B or C virus); interstitial lung disease; previous treatment with
yttrium-90 spheres; treatment with biologic response modifiers (eg, growth
factors) within 3weeks of trial entry;major surgerywithin 4weeks; radiother-
apywithin3weeks;protonpumpinhibitorswithin2weeks; andanycondition
that would interfere with study participation or data interpretation. Medica-
tions prohibited during the trial included proton pump inhibitors, strong
inhibitors of CYP3A4, and biologic response modifiers (except to manage
acute toxicities).
The study protocol was approved by the institutional review board of
each center. All patients provided written informed consent before study-
related procedures.
Random Assignment
Patients were randomly assigned 1:1 to treatment with sorafenib/
erlotinib or sorafenib/placebo, with random assignment stratified by ECOG
performance status (0v1),macrovascular invasion(MVI)and/or extrahepatic
spread (EHS; yes v no), smoking status (current v former v never), and
geographic region (North/South America v Europe/South Africa v Asia-
Pacific). A computer-generated random assignment list was provided in a
blinded fashion to the Interactive Voice Response System/Interactive Web
Response System vendor, with random assignment based on a parallel preal-
located balanced (same weighting per block) design with a block size of four.
The Interactive Voice Response System/Interactive Web Response System
assigned each eligible patient a random assignment number based on treat-
ment allocation and stratification factors and provided the pack number of
sorafenib and erlotinib or placebo to dispense.
Treatment
Patients were treated with sorafenib 400 mg twice a day plus either
erlotinib or placebo 150mg once a day. Patients with treatment-related toxic-
itieswere allowed stepwisedosedelays or reductions, to 400mgonce everyday
and 400 mg once every other day for sorafenib and to 100 mg once every day
and 50 mg once every day for erlotinib or placebo. Patients with grade 1 or 2
toxicitieswere allowed supportive therapy, if available, before considerationof
dose reduction. In patients who experienced grade 3 hematologic toxicities,
study drugs were reduced alternately for every episode of this adverse event
(AE), in a step-by-step fashion, starting with erlotinib or placebo, until reso-
lution to grade  2. The same rule was applied in patients with grade 4
hematologic or grade 3 nonhematologic toxicities, except that treatment with
both drugs was interrupted until resolution to grade 2 before recommenc-
ing at reduced doses. Patients with any grade 4 nonhematologic toxicity had
treatment discontinued.
Erlotinib was interrupted in patients with any grade of suspected or
proven keratitis or suspected interstitial lung disease; if the latter was con-
firmed, both drugs were permanently discontinued. In patients with grade 3
hypertension, both drugs were interrupted until resolution to grade  2,
followed by reinitiation at a reduced dose of sorafenib and unchanged dose of
erlotinib. For subsequent episodes of grade 3 hypertension, study drugs were
reduced alternately step by step, startingwith erlotinib for the second episode.
All patients were monitored for hypertension and treated with antihyperten-
sive drugs.
For patients with grade 3 hand-foot skin reaction (HFSR) and other
nonhematologic toxicities, both drugs were interrupted until resolution to
grade 2 before reinitiation at reduced doses. Study drugs were reduced step
by step startingwith erlotinib or placebo for the first episode and sorafenib for
a second episode. If two ormore toxicities occurred at the same time, the drug
reducedwas the one deemedby the investigatormost likely to have caused the
toxicity. Specified dose interruptions were for  30 days; patients without
sufficient resolution after 30 days were withdrawn.
Treatment compliance was monitored by each patient keeping a Drug
Accountability Form, which included records of the receipt, distribution, and
return of all study medications. The numbers of tablets dispensed to and
returned by each patient were recorded.
Assessments
TheprimaryendpointwasOS,definedas time fromrandomassignment
to death fromany cause; patients remaining alivewere censored at last contact
date. A secondary end point was time to progression (TTP), defined as time
from random assignment to radiologic disease progression, with patients
censoredat last dateof tumorevaluation;patientswhochanged therapybefore
radiologicprogressionwere censoredat the last dateof tumor evaluationwhile
onstudymedication.Other secondaryendpoints includeddisease control rate
(DCR), defined as the percentage of patients with best response of complete
response, partial response, or stable disease, according to RECIST criteria, for
 28 days; overall response rate (ORR), defined as the percentage of patients
with best response of complete or partial response for 28 days; and safety.
Safety was assessed every 3 weeks, and radiologic tumor progression was
assessedevery6weeks.The intensityandseverityofAEsweregradedaccording
to National Cancer Institute Common Terminology Criteria for Adverse
Events (version 3.0). Serious AEs were defined as untoward medical occur-
rences that resulted in death, were life threatening, required inpatient hospi-
talization, prolonged hospitalization, resulted in persistent or significant
disability or incapacity, or were important medical events. Radiologic disease
progression was not centrally reviewed.
Statistical Methods and Analyses
Efficacy was analyzed in the intent-to-treat population, defined as all
randomly assigned patients, and safety was analyzed in all patients who re-
ceivedonedoseof studymedication. Sample size calculationswerebasedon
OS, with a clinically meaningful improvement defined as an OS rate 33%
higher in the sorafenib/erlotinib group than in the sorafenib/placebo group.
Assuming amedianOS for sorafenib/placebo of 10.7months, themedianOS
for sorafenib/erlotinib would have to be 14.3 months, and the hazard ratio
(HR) for sorafenib/erlotinib versus sorafenib/placebowould have to be 0.752.
With a two-sided .05, apowerof 90%, a1:1 randomassignment ratio, and
one formal interim analysis of OS, using an O’Brien-Fleming–type error
spending function, the study required approximately 521 events (deaths), and
approximately 700 patients were planned to be randomly assigned.
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OS and TTP in the two treatment groups were compared using two-
sided log-rank tests with an overall  .05 stratified by ECOG performance
status (0 v 1), MVI and/or EHS (presence v absence), and geographic region
(North/South America v Europe/South Africa v Asia-Pacific). Kaplan-Meier
estimates and survival curves were generated for each treatment group. In
addition,HRs and corresponding 95%CIswere obtainedby aCoxmodel that
includedonly treatment,with stratificationby thepreviouslydescribed factors.
An exploratory analysis of progression-free survival was performed similarly.
Tumor response was evaluated using RECIST version 1.0 criteria, with
DCR and ORR compared using the Cochran-Mantel-Haenszel test, stratified
as forOS.OS in subgroupswas analyzed similarly to the overall intent-to-treat
population. P values for subgroup analyses are provided for descriptive pur-
poses only. All P values reported are two sided.
RESULTS
Patient Characteristics and Disposition
FromMay2009 to January 2011, 962patientswere screened; 720
patientsmet the eligibility criteria andwere randomly assigned, 362 to
the sorafenib/erlotinib group and 358 to the sorafenib/placebo group
(Fig 1); and 362 and 355 patients, respectively, received at least one
dose of studymedication. Overall, the two groups were well matched
in demographic and clinical characteristics (Table 1).
Efficacy End Points
MedianOSwas 9.5months for the sorafenib/erlotinib groupand
8.5months for the sorafenib/placebogroup(HR,0.929; 95%CI, 0.781
to 1.106; P .408; Fig 2A), andmedian TTPwas 3.2 and 4.0months,
respectively (HR, 1.135; 95% CI, 0.944 to 1.366; P .18; Fig 2B). A
post hoc exploratory analysis of progression-free survival showed
results comparable to TTP (HR, 1.111; 95%CI, 0.941 to 1.311).
ORR trended higher in the sorafenib/erlotinib arm than in the
sorafenib/placebo arm (6.6% v 3.9%, respectively; P .102; Table 2).
In contrast, DCR was significantly higher in the sorafenib/
placebo arm than the sorafenib/erlotinib arm (52.5% v 43.9%,
respectively; P  .021).
Subgroup analyses of OS by geographic region (North/South
America, Europe, or Asia-Pacific), disease etiology (hepatitis C, hepa-
titis B, or alcohol), andMVI or EHS (yes or no) showedno significant
Patients screened
(N = 962)
Randomly assigned
(n = 720)
Never treated
(n = 3)
Assigned to receive sorafenib + placebo
(ITT population)
(n = 358)
Assigned to receive sorafenib + erlotinib
(ITT population)
(n = 362)
Received sorafenib + placebo (safety population)
(n = 355)
Received sorafenib + erlotinib (safety population)
(n = 362)
Discontinued sorafenib + placebo (n = 337)
)321 = n( EA na daH  
  Withdrew consent* (n = 24)
)71 = n( †deiD  
  Disease progression, recurrence, (n = 156)
    or relapse
  Withdrawn at investigator’s discretion (n = 2)
)5 = n( pu-wollof ot tsoL  
  Noncompliant/protocol violation (n = 9)
)1 = n( gnissiM  
Continuing to receive randomly (n = 18)
  assigned treatment
Discontinued sorafenib + erlotinib (n = 343)
)711 = n( EA na daH  
)62 = n( tnesnoc werdhtiW  
)13 = n( †deiD  
  Disease progression, recurrence, (n = 155)
    or relapse
  Withdrawn at investigator’s discretion (n = 2)
)3 = n( pu-wollof ot tsoL  
  Noncompliant/protocol violation (n = 8)
)1 = n( gnissiM  
Continuing to receive randomly (n = 19)
  assigned treatment
)242 = n( dedulcxE
  Protocol violation (n = 189)
  Withdrawal of consent (n = 27)
  Adverse event (n = 14)
  Investigator decision (n = 5)
)4 = n( htaeD  
)2 = n( elbaliava toN  
)1 = n( gnissiM  
Fig 1. Patient disposition. (*) Not including one patient who withdrew consent without receiving study drug. (†) Not equivalent to the number of patients who died
on study. See Table 4. AE, adverse event; ITT, intent to treat.
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differences between the sorafenib/erlotinib and sorafenib/placebo
groups (Fig 3). TTP in the stratified subgroups also did not differ
significantly (data not shown). Analysis by smoking status showed
that median OS was approximately 3 months longer for former
smokers (n  260) than for current smokers (n  242) and never-
smokers (n 219), independent of treatment arm.
Treatment Duration and Dosing
The median daily doses per cycle of sorafenib in the sorafenib/
erlotinib and sorafenib/placebo groups were 773 and 768 mg,
respectively, with mean daily doses of 678.9 161.3 and 673.1
156.2 mg, respectively. The median andmean daily doses per cycle
for erlotinib in the sorafenib/erlotinib groupwere 143 and 124.4
32.4 mg, respectively, whereas the median andmean daily doses of
placebo in the sorafenib/placebo group were 142 and 128.2 43.0
mg, respectively.
The median durations of sorafenib treatment in the sorafenib/
erlotinibandsorafenib/placebogroupswere86and123days,respectively.
Themedian andmean durations of treatmentwith erlotinib for patients
in the sorafenib/erlotinib groupwere 86 and 157days, respectively.
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Fig 2. Kaplan-Meier curves of (A) overall survival (OS) and (B) time to progression (TTP) in the sorafenib plus erlotinib (S  E) and sorafenib plus placebo (S  P)
groups. There were 523 events in the OS analysis (255 in the S  E group and 268 in the S  P group) and 469 events in the TTP analysis (240 in the S  E group
and 229 in the S  P group). HR, hazard ratio.
Table 1. Baseline Patient Characteristics
Characteristic
Sorafenib 
Placebo
(n  358)
Sorafenib 
Erlotinib
(n  362)
No. of
Patients %
No. of
Patients %
Median age, years 60.0 60.5
Male 286 79.9 295 81.5
Liver cirrhosis 251 70.1 240 66.3
Ascites 36 10.1 40 11.0
Macroscopic vascular invasion 153 42.7 138 38.1
Extrahepatic spread 219 61.2 205 56.6
Etiology
Hepatitis B 133 37.2 122 33.7
Hepatitis C 84 23.5 107 29.6
BCLC stage
B 48 13.4 60 16.6
C 310 86.6 302 83.4
Child-Pugh score
5 252 70.4 246 68.0
6 93 26.0 110 30.4
ECOG PS
0 216 60.3 222 61.3
1 142 39.7 140 38.7
Geographic region
North or South America 85 23.7 88 24.3
Europe 183 51.1 186 51.4
Asia-Pacific 90 25.1 88 24.3
Smoking status
Never 107 29.9 112 30.9
Former 128 35.8 132 36.5
Current 123 34.4 118 32.6
Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern
Cooperative Oncology Group performance status.
Table 2. Summary of Best Response by RECIST Criteria
Best Response
Sorafenib 
Placebo
(n  358)
Sorafenib 
Erlotinib
(n  362)
P
No. of
Patients %
No. of
Patients %
ORR (CR  PR)† 14 3.9 24 6.6 .102
CR 1 0.3 2 0.6
PR 13 3.6 22 6.1
SD 174 48.6 135 37.3
PD 119 33.2 138 38.1
DCR (CR  PR  SD) 188 52.5 159 43.9 .021
Not assessable 51 14.2 65 18.0 Not assessable
Abbreviations: CR, complete response; DCR, disease control rate; ORR,
overall response rate; PD, progressive disease; PR, partial response; SD,
stable disease.
Two-sided Cochran-Mantel-Haenszel test.
†Intent-to-treat population. Fifty-one patients in the sorafenib plus placebo
group and 65 patients in the sorafenib plus erlotinib were not assessable
for response.
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Sorafenib doses in the sorafenib/erlotinib and sorafenib/placebo
groups were interrupted in 300 patients (82.9%) and 285 patients
(79.6%), respectively, and were reduced in 121 patients (33.4%) and
136 patients (38.0%), respectively. Erlotinib and placebo doses were
interrupted in 258 patients (85.4%) and 252 patients (87.5%), respec-
tively, and were reduced in 217 patients (59.9%) and 211 patients
(58.9%), respectively. Dosing and dose modifications by geographic
region are shown in Table 3.
Safety
In the sorafenib/erlotinib and sorafenib/placebo groups, global
rates of treatment-emergent AEs (100% v 99.2%, respectively), drug-
related AEs (95.0% v 95.2%, respectively), treatment-emergent seri-
ous AEs (58.0% v 54.6%, respectively), and drug-related serious AEs
(21.0% v 22.8%, respectively) were similar.
Table 4 lists the incidenceof treatment-emergentAEsaffecting
15% of patients in either group and the incidence of corresponding
grade 3, 4, or 5AEs.Although theoverallAEprofiles of the twogroups
were similar, there were noticeable differences. AEs that were more
than 5% more frequent in the sorafenib/erlotinib group versus
sorafenib/placebo group included rash/desquamation (51.9% v
40.0%, respectively), anorexia (42.5% v 37.2%, respectively), diarrhea
(76.2% v 59.4%, respectively), and nose bleeding (17.4% v 7.0%,
respectively), whereas AEs that were more than 5%more frequent in
the sorafenib/placebo group versus the sorafenib/erlotinib group in-
cluded alopecia (23.7% v 12.7%, respectively),HFSR (47.6% v 38.1%,
respectively), constipation (20.0% v 12.7%, respectively), cough
(16.9% v 11.0%, respectively), and nausea (31.0% v 24.3%, respec-
tively). The incidence of most treatment-emergent serious AEs was less
than 5% for the entire population, with exceptions possibly reflecting
disease state rather than drug-relatedness, including hepatobiliary/pan-
creas (10.7%), constitutional symptoms (8.6%), infection (7.9%), death
(7.0%),pain(7.0%),andmetabolic/laboratory(5.4%).Individualserious
AE categories with differences across treatment arms of more than 2%
(sorafenib/erlotinib v sorafenib/placebo) were death (8.0% v 5.9%, re-
spectively), infection (6.6% v 9.3%, respectively), metabolic/laboratory
  binitolrE + binefaroS     obecalP + binefaroS   
/stnevE SO naideM /stnevE SO naideM  
)IC %59( RH IC %59 *RH stneitaP )shtnom( stneitaP )shtnom( stneitaP 
 
ITT population 720 8.5 268/358 9.5 255/362 0.929 0.781 to 1.106
 
Region
  Americas 173 8.4 59/85 10.4 58/88 0.892 0.618 to 1.287
  Europe 369 9.8 136/183 9.8 128/186 0.976 0.763 to 1.248
  Asia-Pacific 178 7.4 73/90 7.6 69/88 0.878 0.629 to 1.226
 
Age, years
222.1 ot 787.0 189.0 122/461 9.8 912/071 2.8 044 56 <  
  65 to < 75 203 8.9 73/100 9.4 164/103 0.871 0.612 to 1.238
  ≥ 868.1 ot 385.0 440.1 83/72 8.21 93/52 4.11 77 57 
 
Sex
  Male 581 8.5 221/286 9.2 211/295 0.926 0.762 to 1.126
  Female 139 10.8 47/72 10.3 44/67 1.135 0.708 to 1.821
 
ECOG
820.1 ot 356.0 028.0 222/741 0.11 612/061 7.9 834 0  
264.1 ot 948.0 411.1 041/801 6.7 241/801 3.7 282 1  
 
Smoking status
  Nonsmoker 219 8.5 63/107 8.7 78/112 0.995 0.713 to 1.387
  Former smoker 260 11.4 84/128 11.9 89/132 0.985 0.724 to 1.334
  Current smoker 241 8.0 101/123 8.6 88/118 0.876 0.645 to 1.191
 
Hepatitis B
592.1 ot 237.0 479.0 221/001 9.7 331/901 3.7 552 seY  
761.1 ot 147.0 039.0 042/551 4.01 522/951 6.01 564 oN  
 
Hepatitis C
644.1 ot 876.0 099.0 701/17 3.01 48/75 4.21 191 seY  
101.1 ot 437.0 998.0 552/481 7.8 472/112 0.8 925 oN  
 
Alcohol use
842.1 ot 416.0 578.0 401/07 6.8 98/56 6.8 391 seY  
761.1 ot 777.0 259.0 852/581 5.9 962/302 5.8 725 oN  
 
Macroscopic vascular invasion
790.1 ot 646.0 248.0 831/601 6.7 351/621 5.6 192 seY  
892.1 ot 018.0 520.1 422/941 8.01 502/241 6.11 924 oN  
 
Extrahepatic spread
181.1 ot 857.0 649.0 502/351 7.8 912/171 5.7 424 seY  
012.1 ot 286.0 809.0 751/201 7.01 931/79 7.01 692 oN  
Favors S + E Favors S + P
2.01.0 1.50.5
Fig 3. Forest plot showing subgroup analyses of overall survival. (*) Calculated for sorafenib  erlotinib/sorafenib  placebo. ECOG, Eastern Cooperative Oncology
Group; HR, hazard ratio; ITT, intent to treat; OS, overall survival; S  E, sorafenib plus erlotinib; S  P, sorafenib plus placebo.
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(6.6%v4.2%,respectively),neurology(3.0%v5.6%,respectively),andGI
(15.2% v 10.1%, respectively), with diarrhea accounting for the biggest
difference (4.1% v 0.8%, respectively).
Death rates in the sorafenib/erlotinib and sorafenib/placebo
groupswere similarduring thefirst 30daysof treatment (4.1%v2.5%,
respectively) and up to 30 days after the last dose of studymedication
(21.0% v 18.3%, respectively), with the single highest number of
deaths being a result of liver dysfunction (20 v 18deaths, respectively).
Drug-related deaths attributed to sorafenib in the sorafenib/erlotinib
and sorafenib/placebo groups (nine v 11 deaths, respectively) and
those attributed to erlotinib or placebo (10 v 11 deaths, respectively)
were also similar, with the highest number of deaths caused by liver
dysfunction (two v four deaths in the sorafenib/erlotinib v sorafenib/
placebo group, respectively). Deaths without progression were also
comparable in the sorafenib/erlotinib and sorafenib/placebo groups
(53 v 59 deaths, respectively).
Withdrawal From Treatment
The incidence of treatment-emergent AEs leading to withdrawal
of any drug was similar in the sorafenib/erlotinib (n  163; 45.0%)
and sorafenib/placebo (n 162; 45.6%) groups. Patients in the for-
mer group tended to withdraw from sorafenib earlier as a results of
AEs, with 99 patients (27.3%) receiving sorafenib/erlotinib and 83
patients (23.4%) receiving sorafenib/placebo failing to complete
three cycles of sorafenib as a result of AEs, and 103 patients (28.5%)
and 84 patients (23.7%), respectively, failing to complete three
cycles of erlotinib or placebo as a result of AEs. Causes of with-
drawal with an incidence of  2% in the sorafenib/erlotinib and
sorafenib/placebo groups included fatigue (4.1% v 0.8%, respec-
tively), diarrhea (3.3% v 0.8%, respectively), and dermatologic
(5.0% v 2.3%, respectively).
Table 4. Incidence of Treatment-Emergent AEs With Frequency  15% in Either Group
AE
Sorafenib Plus Placebo (n  355) Sorafenib Plus Erlotinib (n  362)
All Grades Grade 3 Grade 4 Grade 5 All Grades Grade 3 Grade 4 Grade 5
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Any event 352 99.2 180 50.7 46 13.0 72 20.3 362 100.0 179 49.4 56 15.5 80 22.1
Diarrhea 211 59.4 42 11.8 0 0 276 76.2 89 18.5 3 0.8
Fatigue 191 53.8 57 16.1 5 1.4 186 51.4 62 17.1 2 0.6
Hand-foot skin reaction 169 47.6 62 17.5 138 38.1 37 10.2
Rash/desquamation 142 40.0 16 4.5 0 0 188 51.9 31 8.6 2 0.6
Anorexia 132 37.2 20 5.6 154 42.5 15 4.1
Pain, abdomen NOS 115 32.4 24 6.8 1 0.3 116 32.0 21 5.8 1 0.3
Nausea 110 31.0 10 2.8 88 24.3 7 1.9
Weight loss 109 30.7 13 3.7 126 34.8 15 4.1
Ascites 89 25.1 31 8.7 0 0 81 22.4 33 9.1 2 0.6
Hypertension 87 24.5 31 8.7 71 19.6 17 4.7
Alopecia 84 23.7 46 12.7
Vomiting 81 22.8 7 2.0 0 0 79 21.8 7 1.9 1 0.3 0
Edema, limb 73 20.6 5 1.4 81 22.4 4 1.1
Constipation 71 20.0 4 1.1 46 12.7 2 0.6
Fever 70 19.7 1 0.3 77 21.3 2 0.6
Cough 60 16.9 40 11.0
Mucositis, oral 53 14.9 3 0.8 72 19.9 7 1.9
Hemorrhage, nose 25 7.0 0 0 63 17.4 1 0.3
Metabolic/laboratory
Bilirubin (hyperbilirubinemia) 76 21.4 32 9.0 9 2.5 68 18.8 29 8.0 14 3.9
AST 75 21.1 38 10.7 4 1.1 79 21.8 43 11.9 7 1.9
Hemoglobin 50 14.1 15 4.2 6 1.7 68 18.8 23 6.4 6 1.7
Abbreviations: AE, adverse event; NOS, not otherwise specified.
Table 3. Key Study Drug Parameters by Geographic Region in the Intent-to-
Treat Population
Parameter
Americas
(n  173)
Europe
(n  369)
Asia-Pacific
(n  178)
S  P S  E S  P S  E S  P S  E
Sorafenib
Median daily dose, mg 751 764 758 799 776 749
Mean daily dose, mg 667 667 670 694 686 660
Dose interruption, % 82.4 85.2 80.9 84.9 74.4 76.1
Dose reduction, % 48.2 46.6 32.8 23.1 38.9 42.0
Erlotinib
Median daily dose, mg 139 149 132
Mean daily dose, mg 123 126 121
Dose interruption, % 84.1 86.6 76.1
Dose reduction, % 48.9 34.9 42.0
Placebo
Median daily dose, mg 138 142 145
Mean daily dose, mg 127 128 130
Dose interruption, % 84.7 80.9 75.6
Dose reduction, % 42.4 40.4 41.1
Abbreviations: E, erlotinib; P, placebo; S, sorafenib.
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DISCUSSION
Despite sorafenib improvingOS inpatientswithadvancedHCC,most
patients ultimately succumb. This trial, testing whether the combina-
tion of sorafenib and erlotinib improved outcomes in patients with
unresectable HCC, did not meet its primary end point, an improve-
ment in OS. Furthermore, this combination did not significantly
prolong TTP.
Although phase II studies reported that erlotinib mono-
therapy had activity in patients with advanced HCC,17,18 combin-
ing erlotinib with sorafenib did not enhance efficacy compared
with sorafenib alone. Although ORR trended higher in the
sorafenib/erlotinib arm than in the sorafenib/placebo arm (P 
.102), suggesting that the combinationmay result in greater tumor
shrinkage in some patients, the higher response rate did not trans-
late into a prolongation of OS or TTP.
In contrast, DCR (which includes ORR and stable disease) was
significantly lower in the sorafenib/erlotinib group than in the
sorafenib/placebo group (P  .021). Although the daily doses of
sorafenib and erlotinib or placebo were similar in the two groups,
treatment duration was shorter in the sorafenib/erlotinib group than
in the sorafenib/placebo (2.8 v 4.0 months, respectively). Although
this finding suggested an association between treatment duration and
DCR, causality could not be determined. Indeed, longer treatment
duration with sorafenib has been associated with improved clinical
outcomes in patients treated with sorafenib during20 or after21 trans-
catheter arterial chemoembolization.
More patients in the sorafenib/erlotinib group than in the
sorafenib/placebo group discontinued treatment during cycles 1 to 3.
The rate of documentedAEs leading to discontinuationwas higher in
the sorafenib/erlotinib group. From cycle 4 onward, there were no
meaningful between-group differences in dropout rates.
Patients with non–small-cell lung cancer who actively smoke are
less likely to respond to erlotinib and to experience erlotinib-related
toxicity, as a result of its rapidmetabolism and lower drug exposure.22,23
Interestingly, median OS was approximately 3months longer in former
smokers than incurrent andnever-smokers, regardlessof treatmentarm.
Themechanismunderlying these differences is unknown.
Some tyrosine kinase inhibitor–associatedAEs, including erlotinib-
associated erythema24 and sorafenib-associated HFSR,25 may be more
frequent during the first weeks of treatment, with severity and frequency
decreasing thereafter. Sorafenib and erlotinib have overlapping skin tox-
icity profiles, so that additive skin toxicitymay occur during the first two
or three cycles of therapy, possibly resulting inwithdrawals. This hypoth-
esis is difficult to confirm, especially because an erlotinib monotherapy
groupwas not available for comparison.
The overall incidence of AEs was similar in the two groups,
although the incidence of AEs requiring withdrawal from treat-
ment was slightly higher in the sorafenib/erlotinib group. The
higher risk of AEs in the combination group may have been
masked by the relatively longer treatment duration in the
sorafenib/placebo group, explaining why some sorafenib-
associated AEs occurred more frequently in this group.
Our study has several limitations. First, despite the scientific
rationale for targeting EGFR in HCC and the promising results of
phase II trials of erlotinibmonotherapy, no phase II trials assessed the
efficacy and safety of this combination in advanced HCC. Second, as
reported in phase III trials of sunitinib, linifanib, and brivanib,26-29
statistical assumptions were not based on phase II combination data.
Future phase III trials should select agents and regimens with proven
tolerability and favorable safety profiles in HCC-specific phase I trials
anddocumented efficacybasedonwell-designed, preferably random-
ized, phase II trials.30 The lack of synergistic or additive effect suggests
that EGFR signaling may not be pivotal in advanced HCC.
In conclusion, adding erlotinib to sorafenibwas associatedwith a
shorter sorafenib treatment duration and did not improve survival in
patients with advanced HCC. Sorafenib remains the standard of care
for first-line treatment of advanced HCC.
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